DarioHealth Reports Record Quarterly Revenues in its 2022 First Quarter

Rhea-AI Summary

DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q1 2022, posting revenues of $8.06 million, a 124% increase year-over-year and a 34% rise sequentially. Gross margins expanded to 49.4% (GAAP) and 61% (non-GAAP). The company added 14 new B2B accounts, including two health plans, and secured a $30 million agreement with Sanofi to enhance its market outreach. Despite an operating loss of $15.9 million, DarioHealth improved its financial position by reducing operating costs and marketing expenses, indicating a positive trend in its B2B transformation.

Positive

• Revenue increased to $8.06 million, up 124% YoY and 34% QoQ.
• Gross margins improved to 49.4% (GAAP) and 61% (non-GAAP).
• Added 14 new B2B accounts in Q1 2022, including two health plans.
• Secured a $30 million multi-year agreement with Sanofi.
• Reduced cash burn and improved overall financial profile.

Negative

• Operating loss increased to $15.9 million, up 10.8% YoY.
• Operating expenses rose to $19.9 million, 28.9% higher than Q1 2021.

Total Q1 revenue of $8.06 million increased 124% over the comparable prior year period and 34% sequentially over Q4 2021

Accelerated Business-to-Business (B2B) transformation with 14 new B2B accounts in Q1 2022, including two health plans

Expanded GAAP gross margin to 49.4% and non-GAAP gross margin to 61%

Improved overall financial profile with increasing B2B revenue and reduced operating costs as B2B business matures resulting in a lower net loss compared to Q4 2021

Company to host conference call and webcast 8:30 am ET today

NEW YORK, May 12, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today reported financial results for the first quarter 2022 and provided a corporate and commercial update.

"Our first quarter results reflect our increasingly successful transition to a B2B model with growing revenue and gross margins," stated Erez Raphael, Chief Executive Officer of Dario. "We increased revenue nearly 124% over the first quarter of last year and nearly 34% sequentially, and we expanded our gross margin on a GAAP basis to 49.4% and on a non-GAAP basis to 61%. Additionally, in light of the demonstrable traction and increasing revenue in the B2B (commercial) market segment, we continued to rationalize marketing spend in the direct-to-consumer segment resulting in improved margins which drove a significantly narrower net loss and cash burn rate as compared to the fourth quarter of 2021.With the strategic agreement executed with Sanofi U.S. (Sanofi) and the $40 million financing that we closed in the quarter, we believe that we are in an excellent position to achieve our financial and operational goals for the foreseeable future," Mr. Raphael concluded.

"In addition to the innovative, multi-year collaboration that we announced with Sanofi, we had a very productive quarter, adding 14 new B2B contracts, including two additional health plans, which we expect will contribute revenues in the back half of this year," stated Rick Anderson, President and General Manager of North America. "We continue to see increasing interest and demand for our integrated, multi-chronic condition platform, which continues to grow, and we anticipate announcing many more customer conversions from our growing pipeline over the remainder of the year."

Q1 2022 and Recent Highlights

• Generated total revenue of $8.06 million, representing an increase of 124% from the first quarter of 2021, and 34% from the fourth quarter of 2021.
• Added 14 new accounts across the employer, health plan and provider channels during Q1, reflecting continued momentum of B2B segment.
• Signed a multi-year, multi-faceted $30 million agreement with Sanofi to accelerate adoption of Dario's solution within the payer channel through joint sales efforts and drive innovation through shared research initiatives and development of new products for use on Dario's platform.
• Expanded GAAP gross margins to 49.4% and non-GAAP gross margins to 61%.
• Raised $40 million through a registered direct offering priced at the market.
• Announced acquisition of Physimax, a leading provider of validated computer vision for musculoskeletal health.
• Presented new clinical research demonstrating improved outcomes for participants using a single integrated digital solution to manage multiple chronic conditions at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference, held April 27^th – 30^th.

First Quarter 2022 Results Summary

Revenues for the first quarter ended March 31, 2022, were $8.06 million, a 34% sequential increase from fourth quarter ended December 31, 2021, and a 124% increase from the $3.6 million in the first quarter ended March 31, 2021. The increase in revenues resulted from increased revenues in our B2B commercial market segment.

Gross profit in the first quarter of 2022 was $4.0 million, an increase of $2.9 million, compared to gross profit of $1.1 million in the first quarter of 2021. Gross profit as a percentage of revenues increased from 30.1% in the first quarter of 2021 to 49.4% in the first quarter of 2022.

Pro-forma gross profit, excluding $932,000 of non-cash amortization of expenses related to the acquisition of technology, was $4.9 million, or 61% of revenues, for the three months ended March 31, 2022.

Total operating expenses for the first quarter of 2022 were $19.9 million compared with $15.4 million for the first quarter of 2021 and $22.2 million in the fourth quarter of 2021, an increase of $4.5 million, or 28.9%, compared to the first quarter of 2021, and a decrease of $2.3 million, or 10.6%, compared to the fourth quarter of 2021. The increase compared to the first quarter of 2021 resulted from an increase in our operating expenses. The decrease compared to the fourth quarter of 2021 resulted from a decrease in our direct to consumer marketing expenses. Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2022 were $14.8 million compared to $10.6 million for the first quarter of 2021, and $16.4 million in the fourth quarter of 2021.

Operating loss for the first quarter of 2022 was $15.9 million, an increase of $1.55 million, or 10.8%, compared to the $14.3 million operating loss in the first quarter of 2021, and a decrease of $5.8 million or 26.7% compared to the $21.7 million operating loss in the fourth quarter of 2021. The increase compared to the first quarter of 2021 was mainly due to the increase in our operating expenses, and the decrease compared to the fourth quarter of 2021 was mainly due to the increase in the gross profit and the decrease in operating expenses.

Net loss was $15.9 million in the first quarter of 2022, an increase of $0.9 million, or 6.3%, compared to the $15 million net loss in the first quarter of 2021, and a decrease of $5.7 million, or 26.3% compared to the fourth quarter of 2021. Net loss excluding stock-based compensation, acquisition expenses and depreciation for the first quarter of 2022 was $9.9 million compared to $9.6 million for the first quarter of 2021 and $14.9 million in the fourth quarter of 2021.

Non-GAAP billings for the three months ended March 31, 2022, were $7.96 million, a 116% increase from $3.69 million reported for the three months ended March 31, 2021. The increase is a result of higher sales generated in the three months ended March 31, 2022, compared to the three months ended March 31, 2021. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Conference Call Details: Thursday, May 12, 8:30am ET

Dial-in Number: 844-826-3035

International Dial-in: 412-317-5195

Conference ID:  DarioHealth First Quarter 2022 Results Call

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1547229&tp_key=ae83ab1839

Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through June 12, 2022. To listen to the replay, dial 844-512-2921 (domestic) or 412-317-6671 (international) and use replay passcode 10166824.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.

Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.

Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.

The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.

On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that its first quarter results reflect its increasingly successful transition to a B2B model with growing revenue and gross margins, the belief that it is in an excellent position to achieve its financial and operational goals for the foreseeable future, the expected timing of the contribution of revenues from its new B2B contracts, the interest and demand seen for its platform and its anticipation of announcing many more customer conversions from its growing pipeline over the remainder of the year. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.

Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.

Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expense provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.

Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory and depreciation of fixed assets. We believe these measures provide useful information to management and investors for analysis of our operating results.

 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
		March 31,			December 31,
		2022			2021
		Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	55,558		$	35,808
Short-term restricted bank deposits			190			192
Trade receivables			4,574			1,310
Inventories			7,783			6,228
Other accounts receivable and prepaid expenses			3,271			2,067
Total current assets			71,376			45,605
NON-CURRENT ASSETS:
Deposits			7			20
Operating lease right of use assets			280			287
Long-term assets			16			57
Property and equipment, net			698			702
Intangible assets, net			13,314			12,460
Goodwill			41,640			41,640
Total non-current assets			55,955			55,166
Total assets		$	127,331		$	100,771

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except stock and stock data)
		March 31,			December 31,
		2022			2021
		Unaudited
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables		$	4,228		$	5,109
Deferred revenues			1,093			1,195
Operating lease liabilities			212			266
Other accounts payable and accrued expenses			7,192			7,806
Earn out liability			373			825
Total current liabilities			13,098			15,201
NON-CURRENT LIABILITIES
Operating lease liabilities			48			21
Total non-current liabilities			48			21
STOCKHOLDERS' EQUITY
Common stock of $0.0001 par value - Authorized: 160,000,000 shares at     March 31, 2022 (unaudited) and December 31, 2021; Issued and     Outstanding: 22,070,963 and 16,573,420 shares at March 31, 2022     (unaudited) and December 31, 2021, respectively			2			2
Preferred stock of $0.0001 par value - Authorized: 5,000,000 shares at     March 31, 2022 (unaudited) and December 31, 2021; Issued and     Outstanding: 10,897 and 11,927 shares at March 31, 2022 (unaudited)     and December 31, 2021, respectively			*) -			*) -
Additional paid-in capital			352,564			307,561
Accumulated deficit			(238,381)			(222,014)
Total stockholders' equity			114,185			85,549
Total liabilities and stockholders' equity		$	127,331		$	100,771

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
U.S. dollars in thousands (except stock and stock data)
		Three months ended
		March 31,
		2022			2021
		Unaudited
Revenues		$	8,059		$	3,595
Cost of revenues (excluding of amortization and inventories step-up shown separately below)			3,142			1,988
Amortization of acquired intangible assets and inventories step-up			932			526
Gross profit			3,985			1,081
Operating expenses:
Research and development		$	5,927		$	2,655
Sales and marketing			9,535			7,132
General and administrative			4,395			5,621
Total operating expenses			19,857			15,408
Operating loss			15,872			14,327
Total financial expenses, net			44			639
Net loss		$	15,916		$	14,966
Deemed dividend		$	451		$	544
Net loss attributable to holders of common stock		$	16,367		$	15,510
Net loss per share:
Basic and diluted loss per share		$	0.74		$	0.92
Weighted average number of common stock used in computing basic   and diluted net loss per share			19,624,079			14,025,921

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
		Three months ended
		March 31,
		2022			2021
		Unaudited
Cash flows from operating activities:
Net loss		$	(15,916)		$	(14,966)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation, common stock, and payment in stock to directors,        employees,consultants, and service providers			5,343			4,438
Depreciation			70			64
Change in operating lease right of use assets			7			6
Amortization of acquired inventories step-up			-			151
Amortization of acquired intangible assets			963			375
Decrease (increase) in trade receivables			(3,264)			318
Decrease (increase) in other accounts receivable, prepaid expense and long-term assets			(1,550)			207
Increase in inventories			(1,555)			(32)
Increase in trade payables			(890)			(544)
Decrease in other accounts payable and accrued expenses			(721)			(609)
Increase (decrease) in deferred revenues			(102)			93
Change in operating lease liabilities			(27)			(33)
Remeasurement of earn-out			(452)			-
Net cash used in operating activities			(18,094)			(10,532)
Cash flows from investing activities:
Purchase of property and equipment			(66)			(68)
Cash paid as part of Upright Technologies Ltd. acquisition			-			(2,472)
Intangible assets purchases incurred, Physimax Technologies LTD.			(115)			-
Net cash used in investing activities			(181)			(2,540)
Cash flows from financing activities:
Proceeds from issuance of common stock and prefunded warrants net of issuance costs			38,023			64,877
Proceeds from exercise of warrants			-			633
Proceeds from exercise of options			-			201
Net cash provided by financing activities			38,023			65,711
Increase in cash, cash equivalents and restricted cash and cash equivalents			19,748			52,639
Cash, cash equivalents and  restricted cash and cash equivalents at beginning of period			35,948			28,725
Cash, cash equivalents and restricted cash and cash equivalents at end of period		$	55,696		$	81,364

 

 

Reconciliation of Revenue to Billing (Non-GAAP)
U.S. dollars in thousands
		Three Months Ended March 31,
		2022		2021
GAAP Revenue		8,059		3,595
Add:
Change in deferred revenue		(102)		93
Billing (Non-GAAP)		7,957		3,688

 

 

Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted
Operating Loss, Net Loss and Operating Expenses (Non-GAAP)
U.S. dollars in thousands
Three months ended March 31, 2022
	GAAP		Stock-Based Compensation Expenses		Earn-out revaluation, acquisition costs, amortization of acquisition related expenses and depreciation of fixed assets		Non-GAAP
Cost of Revenues	$	4,074		(23)		(954)		3,097
Gross Profit		3,985		23		954		4,962
Research and development		5,927		(1,488)		(11)		4,428
Sales and Marketing		9,535		(1,651)		(41)		7,843
General and Administrative		4,395		(2,181)		338		2,552
Total Operating Expenses		19,857		(5,320)		286		14,823
Operating Loss	$	(15,872)		5,343		668		(9,861)
Financing income		44		-		-		44
Income Tax		-						-
Net Loss	$	(15,916)		5,343		668		(9,905)

 

 

Three months ended March 31, 2021
	GAAP		Stock-Based Compensation Expenses		Amortization of acquisition Related expenses and depreciation of Fixed Assets		Non-GAAP
Cost of Revenues	$	2,514		(13)		(557)		1,944
Gross Profit		1,081		13		557		1,651
Research and development		2,655		(414)		(15)		2,226
Sales and Marketing		7,132		(1,035)		(11)		6,086
General and Administrative		5,621		(2,976)		(385)		2,260
Total Operating Expenses		15,408		(4,425)		(411)		10,572
Operating Loss	$	(14,327)		4,438		968		(8,921)
Financing income		639		-		-		639
Net Loss	$	(14,966)		4,438		968		(9,560)

 

 

 

DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing   
suzanne@dariohealth.com
+1-347-767-4220

Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262

View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-record-quarterly-revenues-in-its-2022-first-quarter-301545831.html

SOURCE DarioHealth Corp.

FAQ

What were DarioHealth's Q1 2022 revenue figures?

DarioHealth reported revenues of $8.06 million for Q1 2022.

How much did DarioHealth's revenue increase compared to Q1 2021?

Revenue increased by 124% compared to Q1 2021.

What is the gross margin for DarioHealth in Q1 2022?

DarioHealth's gross margin expanded to 49.4% (GAAP) and 61% (non-GAAP) in Q1 2022.

How many new B2B accounts did DarioHealth add in Q1 2022?

DarioHealth added 14 new B2B accounts during Q1 2022.

What financial agreement did DarioHealth sign in Q1 2022?

DarioHealth signed a $30 million multi-year agreement with Sanofi in Q1 2022.

What was DarioHealth's net loss in Q1 2022?

DarioHealth reported a net loss of $15.9 million in Q1 2022.